EUCTR2006-002850-31-GB进行中（未招募）1 期
APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemopoietic stem cell transplantation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •The inclusion criteria are:
- •Immunophenotypic (monoclonal population of mature CD5+, CD19+, CD23+) confirmed diagnosis of B-CLL
- •Diagnosis of progressive symptomatic B-CLL requiring therapy (Revised NCI-sponsored Working Group guidelines for CLL (Cheson 1996: see Appendix B)
- •Relapsed or refractory disease or intolerant to = 2 prior systemic therapy (containing either a purine analog or an alkylating agent). Patient is not amenable to aHSCT
- •ECOG Performance Status = 2 (see Appendix C)
- •Age = 18 years, of either sex
- •Female patients with childbearing potential must be using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Women of childbearing potential must have a negative serum or urinary hCG pregnancy test within 7 days prior to Study Day 1 (SD1)
- •Male patients, who are not surgically sterile, must use a condom with spermicide for the duration of the study and 3 months thereafter
- •Have given written informed consent, prior to any study related procedure not part of the patient’s normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The exclusion criteria are:
- •Have participated in any other investigational study or received an experimental therapeutic procedure considered to interfere with the study in the 4 weeks preceding SDI.
- •Use of prohibited medication due to CYP3A4 metabolism of APO866, as specified in Section 6.6.2. concomitant use of these drugs will not be allowed during the study.
- •Use of biphosphonate drugs during the 30 days preceding the APO866 perfusion and during the treatment period.
- •Uncontrolled medical conditions, requiring surgical or pharmacological treatment (exceptions must be approved by the Medical Responsible of the study).
- •Active infection requiring systemic antibiotics
- •Serious concomitant disease (e.g. significant cardiac disease)
- •History of second cancer that was treated with curative intent and in complete remission for < 5 years, with the exception of basal cell carcinoma or cervical cancer in situ
- •Inadequate bone marrow function: platelets = 75x109/L without transfusion in the preceding 2 weeks, ANC = 1,0x109/L without growth factor support, abnormal coagulation APTT an PT
- •Platelet-refractory state due to platelet alloimmunization
- •Inadequate liver function: total bilirubin > 1.5x upper limit of normal values (ULN), AST, ALT, or alkaline phosphatase > 2.5x ULN
- •Inadequate renal function: serum creatinine = 1.5x ULN
- •Retinopathy, history of retinal laser surgery, or an ERG < 50% of normal
- •Pregnant or lactating female
- •Known allergy to reagents in the study drug (APO866 or propylene glycol).
研究者
相似试验
已完成
不适用
Acute lymphoblastic leukaemia (ALL) trial XII (joint trial with Eastern Co-operative Oncology Group - E2993)eukaemiaCancerLeukaemiaISRCTN77346223Medical Research Council (MRC) (UK)550
已完成
1 期
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell LymphomaLymphomaNCT00446095Rigel Pharmaceuticals81
招募中
1 期
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelNon-Hodgkin LymphomaLarge B-cell LymphomaNCT05794958Stanford University20
已完成
2 期
Phase II clinical trials of mature B-cell neoplasms in children: A Japanese Cooperative Studiesmature B-cell non-Hodgkin's lymphoaJPRN-C000000317Japanese Pediatric Leukemia/Lymphoma Studu Group(JPLSG)308
招募中
不适用
Bridging therapy of acute lymphoblastic leukemia before treatment with chimeric antigen receptor (CAR) T cells - Retrospective analysis for a guidanceC91.0Acute lymphoblastic leukaemia [ALL]DRKS00024916Dr. von Haunersches Kinderspital Klinikum der Universität München35